<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893643</url>
  </required_header>
  <id_info>
    <org_study_id>18-DERMATO-01</org_study_id>
    <nct_id>NCT03893643</nct_id>
  </id_info>
  <brief_title>Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15</brief_title>
  <official_title>Multicentre Prospective Observational Study: Resentment of Mucocutaneous Manifestations and the Value of Dermatological Examination in the Early Detection of Type 2 Neurofibromatosis in Children Under 15 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      .Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of
      mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 / 60,000.
      the clinical presentation is based on the appearance of tumors in the central and peripheral
      nervous system. The current average age of diagnosis is around 25 to 30 years depending on
      the studies. Currently, the diagnostic criteria are based on the ENT, neurological and
      opthalmological manifestations of the disease. Cutaneous manifestations have been described
      in these patients. Except now, mucocutaneous manifestations of the disease are not taken into
      account for depisatage or diagnosis.

      The purpose of this study would be to identify the different cutaneous and mucosal
      manifestations in a pediatric population under 15 years of age, and to analyze whether this
      might be of interest in early detection of the disease in association with other symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of cutaneo-mucous lesions present in children with neurofibromatosis type 2</measure>
    <time_frame>3 years</time_frame>
    <description>number of cutaneo-mucous lesions obtain after complete dermatological clinical examination ; if possible take photographs for publication with the patient's consent ; histological results if cutaneous biopsies were performed outside the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number and type of neurological manifestations.</measure>
    <time_frame>3 years</time_frame>
    <description>number and type of neurological clinical data, clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and type of descriptioin of ENT manifestations.</measure>
    <time_frame>3 years</time_frame>
    <description>number and type of ENT clinical data, clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and type of ophthalmological manifestations.</measure>
    <time_frame>3 years</time_frame>
    <description>number and type of ophtalmologic clinical data, clinical examination</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Neurofibromatosis 2</condition>
  <condition>Dermatology/Skin - Other</condition>
  <arm_group>
    <arm_group_label>pediatric population</arm_group_label>
    <description>Pediatric population aged 0 to 15 years with neurofibromatosis type 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention in an observational study</description>
    <arm_group_label>pediatric population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with neurofibromatosis type 2
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age up to 15 years

          -  diagnosis of neurofibromatosis type 2

        Exclusion Criteria:

          -  refusal to participate in the study

          -  informed consent that can not be obtained because of a disability or difficulties with
             a - language barrier
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie LEGOUPIL</last_name>
    <phone>336 81818020</phone>
    <email>sophie.legoupil@hotmail.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine CHIAVERINI</last_name>
    <email>chiaverini.c@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nice Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie LEGOUPIL</last_name>
      <email>legoupil.sophie@hotmail.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christine CHIAVERINI</last_name>
      <email>chiaverini.c@chu-nice.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibromatosis 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

